T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1651
Urban Edge Properties
UE
$2.76B
| $2.46M | ﹤0.01% |
128,021
+4,007
| +3% | +$77.7K |
|
1652
Integer Holdings
ITGR
$4.26B
| $2.45M | ﹤0.01% |
31,289
+1,896
| +6% | +$151K |
|
|
GTM
1653
ZoomInfo Technologies
GTM
$1.19B
| $2.45M | ﹤0.01% |
241,297
-2,591,925
| -91% | -$26.7M |
|
1654
CBIZ
CBZ
$2.96B
| $2.45M | ﹤0.01% |
48,606
+2,733
| +6% | +$144K |
|
1655
First Hawaiian
FHB
$3.36B
| $2.45M | ﹤0.01% |
96,740
+4,458
| +5% | +$111K |
|
1656
Oceaneering
OII
$5.2B
| $2.44M | ﹤0.01% |
101,308
+8,260
| +9% | +$200K |
|
1657
Blackbaud
BLKB
$2.07B
| $2.43M | ﹤0.01% |
38,413
+2,185
| +6% | +$135K |
|
1658
Omnicell
OMCL
$1.7B
| $2.43M | ﹤0.01% |
53,571
+2,004
| +4% | +$73.3K |
|
1659
Dave Inc
DAVE
$4.3B
| $2.43M | ﹤0.01% |
10,954
+4,388
| +67% | +$944K |
|
1660
CoreCivic
CXW
$3.17B
| $2.42M | ﹤0.01% |
126,618
-87,023
| -41% | -$1.59M |
|
1661
Aura Biosciences
AURA
$793M
| $2.42M | ﹤0.01% |
442,789
-38,442
| -8% | -$228K |
|
1662
Brookdale Senior Living
BKD
$3.03B
| $2.4M | ﹤0.01% |
222,476
+12,991
| +6% | +$128K |
|
1663
Cabaletta Bio
CABA
$448M
| $2.4M | ﹤0.01% |
1,093,959
-200,990
| -16% | -$498K |
|
1664
O-I Glass
OI
$1.05B
| $2.4M | ﹤0.01% |
162,309
+6,994
| +5% | +$92.5K |
|
1665
Kohl's
KSS
$2.21B
| $2.39M | ﹤0.01% |
117,004
-14,013
| -11% | -$263K |
|
|
APLS
1666
DELISTED
Apellis Pharmaceuticals
APLS
| $2.39M | ﹤0.01% |
95,035
-2,905
| -3% | -$68.2K |
|
1667
TFI International
TFII
$12.1B
| $2.38M | ﹤0.01% |
22,984
-8,967
| -28% | -$835K |
|
|
HAPN
1668
Happen Inc
HAPN
$2.27B
| $2.36M | ﹤0.01% |
124,712
-765,526
| -86% | -$13.5M |
|
1669
Simmons First National
SFNC
$3.48B
| $2.36M | ﹤0.01% |
125,326
+4,507
| +4% | +$83.5K |
|
1670
ABM Industries
ABM
$2.83B
| $2.36M | ﹤0.01% |
55,824
+3,789
| +7% | +$166K |
|
1671
Trustmark
TRMK
$2.8B
| $2.36M | ﹤0.01% |
60,517
+1,473
| +2% | +$57.3K |
|
1672
Four Corners Property Trust
FCPT
$2.78B
| $2.35M | ﹤0.01% |
101,790
+7,869
| +8% | +$187K |
|
1673
Penske Automotive Group
PAG
$14.4B
| $2.35M | ﹤0.01% |
14,827
+363
| +3% | +$59.7K |
|
1674
Provident Financial Services
PFS
$3.22B
| $2.34M | ﹤0.01% |
118,462
+4,332
| +4% | +$83.8K |
|
1675
Goodyear
GT
$1.76B
| $2.34M | ﹤0.01% |
266,909
+22,219
| +9% | +$175K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.